INTRODUCTION
Immunoglobulin half-molecules consisting of one heavy and one light chain are rare. IgG half-molecules were This is Scripps Clinic and Research Foundation Publication No. 953.
Received for publication 6 March 1975 and in revised form 28 April 1975. first detected in the serum of colostrum-deprived piglets (1, 2) , and later IgA half-molecules were found in the urine of mice bearing certain mineral oil-induced IgA plasmacytomas (3) . Hobbs and Jacobs reported the first patient with a plasmacytoma who produced half-molecules (4) , and since then four more such patients have been detected (5) (6) (7) . The half-molecules production does not appear to be associated with a distinct clinical syndrome since three patients had extramedullary plasmacytomas (5) , one plasma cell leukemia (6) , and one classical multiple myeloma (M. Seligmann, personal communication). Nevertheless, all these patients had in common that they excreted large amounts of half-molecules into their urine. Detailed structural analysis of the paraprotein of our patient (8) revealed that it lacked the noncovalent interactions characteristic for the Fc portion of the 'v-chain and that it had a deletion in the third constant domain (Cy3)' of the heavy chain. The size of the deletion was 5,000-8,000 daltons. It probably involved the intrachain disulfide loop of the C'v3 domain but not the carboxyterminal structure of the gamma chain. The half-molecule expressed the genetic marker Gm (f) which is localized on the CO1 domain but lacked the corresponding marker Gm(non-a) as well as another marker on the C'Y3 domain. The "hinge" peptide containing the inter-heavy-heavy chain disulfide bonds appeared intact and its amino acid composition was identical to the corresponding peptide of IgG1 proteins. This explained why the patient formed also a small amount of four-chain 7S type myeloma protein.
In order to investigate the biological properties of this unusual myeloma protein, we measured its rates of elimination from the circulation and excretion into the urine, its capacity to fix complement, and its ability to bind to the Fc receptors of human white cells and guinea pig mast cells.
METHODS
Isolation of proteins. The myeloma protein of patient K. N. was isolated from his plasma and urine by a combination of DEAE-cellulose chromatography and Sephadex G-200 gel filtration (8). The half-molecule was obtained from either serum or urine in a relatively pure form whereas the 7S IgG serum fraction contained only about 35% myeloma protein, the remaining portion being normal IgG (8). IgG1 (Ma) and IgG2 (Do) myeloma proteins and normal human IgG were isolated by DEAE-cellulose chromatography using a 0.01 M phosphate buffer, pH 8.0. An IgM macroglobulin (Vi) was isolated by a combination of euglobulin precipitation, Pevikon block electrophoresis, and Sephadex G-200 gel filtration. The Fab fragment was isolated from either normal IgG or the half-molecule after digestion with papain for 18 h (8).
Aggregation of proteins. Three methods were used to aggregate the proteins for the different test methods. For complment fixation, the proteins were aggregated either by addition of 200 pLg/5 mg of bis-diazotized benzidine (9) or by heating at 630C for 5-30 min until the solution became slightly turbid. For the experiments designed to measure the binding to different cell types, the proteins were aggregated with a F(ab')2 preparation of a rabbit anti-human Fab fragment antiserum (10) . The F(ab')2 anti-Fab antiserum precipitated immunoglobulins of all classes and light chain types when tested by double gel diffusion analysis.
Radioiodination. All proteins were radioiodinated with either 'I or 'I by using modifications of the chloramine T procedure. For turnover studies, protein in 5-mg aliquots was dissolved in 1 ml 0.05 M phosphate buffer, pH 7.0, and was labeled with 10 pg of chloramine T/mg by incubating for 5 min (11) . The uptake of radioactivity varied between 35 and 60% and the specific radioactivity was about 0.1 pCi/pg. 95-97%o of the half-molecule and 98-99%o of the 7S IgG preparations were precipitable as protein bound radioactivity at a concentration of 10%o trichloroacetic acid (TCA). For determination of the protein's ability to bind to cells, they were labeled with 'I by a chloramine T procedure that yielded high specific activity of 20-40 GCi/Ag (12) . The radioactivity of the 1"I-and 'MI-labeled proteins as well as mixtures of the two isotopes were determined in a dual channel scintillation counter (Baird Atomic, Inc., Cambridge, Mass.).
Turnover studies. The protocol that has previously been described was used for turnover studies (13, 14) . One study of the half-molecule isolated from the serum of patient K. N. was performed by injecting it into the author and other studies were done in monkeys of the macaca family (M. mulatta, M. nemestrina, and M. speciosa). No difference was observed in the different species. All labeled proteins were injected within 2 days after labeling. To remove any aggregates and to render the monkeys unresponsive to human IgG (14) , the proteins were centrifuged at 40,000 rpm for 60 min immediately before injection. In man, 10 min after injection the first blood sample was drawn from the vein of the opposite arm used for injection and in monkeys after 5 min from the opposite leg (vena saphena).
The plasmas of these first blood samples were used as the value for the 100% plasma concentration on day 0.
Urine was collected into plastic containers over 24-h periods, an aliquot cleared by centrifugation, and the total and protein bound radioactivity determined. 0.1 ml of normal serum was added per milliliter of urine as protein carrier in order to determine the protein bound radioactivity precipitable by 10%o TCA.
The plasma half-lives and the percent intra-and extravascular distribution was calculated from the semilogarithmic plot of the plasma elimination curve. The total body half-life in man was calculated from the slope of the semilogarithmic plot of the radioactivity retained in the body (total injected radioactivity minus accumulated radioactivity excreted into the urine). The whole body elimination could not be determined in this manner in monkeys because complete daily urine collections could not be made. The fractional turnover rate was calculated from the radioactivity excreted into the urine per day expressed as percent of the average intravascular pool in the same 24-h period (15) .
In order to determine the molecular size of the protein precipitable with TCA in the urine, the urine of a monkey injected with 'I-labeled half-molecule was collected during the first 6 h after injection. 2 Reverse passive cutaneous anaphylaxis (RPCA). The ability of the myeloma proteins to bind to guinea pig skin and induce RPCA reaction was studied as described by Terry (17) . Hartley guinea pigs were injected at several sites with 0.1 ml of a saline solution containing 0.1, 1, and after 30 min when the animals were sacrificed, skinned, and the blueing reaction measured inside the skin. RESULTS Turnover studies. The whole body and plasma elimination curves in man of the "I-labeled half-molecule isolated from the serum of patient K. N. are shown in Fig. 1 . The turnover calculations are presented in Table I together with values obtained for normal IgG and gamma chain disease proteins in a previous study performed under the same conditions (14) . The halfmolecule was rapidly eliminated from the circulation and catabolized, the whole body half-life being 4.3 days and the plasma half-life 3.8 days. About 7% of the injected radioactivity remained in the intravascular compartment. An average of 165% of the intravascular pool was catabolized per day or 6.7% per h. Although the fractional turnover varied slightly from day to day (148-182%), it was no greater during the first 3 days after injection (155, 182, and 161%) than later. The semilogarithmic plot of the whole body elimination was, Additional turnover studies in monkeys showed almost identical plasma elimination curves to those seen in the human study (Fig. 2) 
7S
IgG myeloma protein fractioned with the normal IgG, suggesting no significant change in molecular weights of the labeled proteins. A similar experiment was performed in order to determine if the protein-bound radioactivity in the urine of monkeys represented intact half-molecules or fragments thereof. As can be seen in Fig. 3 , the protein-bound radioactivity of the urine eluted as a single peak at the position of 5S proteins, such as albumin, which is characteristic for the halfmolecule. A second peak of "'I eluted just before the reagent peak and this radioactivity was not TCA precipitable. It most likely represented either free 15I or 'I bound to small peptides or tyrosine or both that were not removed by dialysis during the overnight period. The predominant equilibration of the half-molecule into the extravascular space could have been the result of an autoantibody-like activity of the Fab fragment to a tissue antigen. In order to test this hypothesis, the elimination of the Fab fragment of the half-molecule was compared with that of normal Fab fragments. However, the two preparations, after being paired-labeled and injected into monkeys, were eliminated and excreted into the urine in an almost identical manner. The plasma elimination curves did not differ significantly during the first 3 days after injection from those of the half-molecule but afterwards were more rapid with half-lives of 1.8-2.2 days. The portion that remained in the intravascular compartment was 12-13% as determined by extrapolation of the plasma elimination curve.
10-13% of the radioactivity excreted in the urine was TCA precipitable.
Complement fixation. The ability of the half-molecule and the 7S IgG myeloma protein fraction to form complexes with Clq is shown in Fig. 4 (18) . The half-molecule was very rapidly catabolized and in part excreted into the urine. The unaggregated half-molecule failed to form complexes with the complement component Clq and to bind to Fc receptors of human lymphocytes, neutrophils, and monocytes or to guinea pig mast cells. In contrast, the aggregated half-molecule fixed hemolytic complement and bound to lymphocytes, neutrophils, and monocytes, indicating that it did not lack all the structures on the Fc fragment responsible for these biological activities. The covalent four-chain 7S myeloma protein could not be obtained in pure form because the patient's serum contained only a small quantity of such molecules. However, a significant portion of the 7S myeloma protein preparation was rapidly catabolized, suggesting that the 7S myeloma protein also lacked the structures responsible for a slow turnover. Whether an essential structure was missing or the deletion caused a change in the overall configuration resulting in lack of expression of the active site are presently unknown. The ability of the aggregated proteins to fix complement and bind to cells suggests that the sites responsible for secondary biological functions are not totally absent but that the affinity of the remaining site in the unaggregated protein is too low to bind effectively. It appears from these studies that only a relatively intact Fc fragment can mediate the secondary biological functions normally.
The short survival and excretion into the urine of the half-molecule were markedly different from those of Fc fragments and gamma chain disease proteins (14, 19) but were similar to those of the half-molecule's Fab fragment and of Bence Jones proteins (20) . One explanation for the fast turnover and excretion of the half-molecule could have been fragmentation and alteration occurring during the labeling procedure. However, no evidence for fragmentation or aggregation of the labeled myeloma protein was obtained. Furthermore, Fc fragments and gamma chain disease proteins labeled under the same conditions showed long plasma half-lives and a low rate of excretion into the urine (14) . Moreover, the patient's clinical manifestations also indicated that the half-molecule turns over rapidly. The serum of the patient showed only a modest 1.5 g/100 ml myeloma spike despite general myeloma involvement, and he excreted 300 mg/100 ml of half-molecules into the urine in the absence of overt renal failure (6) . It appears most likely, therefore, that the half-molecule as well as 7S myeloma protein had rapid turnovers because they did 592 not express sites on their Fc fragments that are necessary for the characteristic slow catabolism of IgG.
The biphasic whole body elimination curve is not fully understood. Although it could be the result of alteration of a large portion of the labeled protein, it could also be the result of the rapid turnover of the half-molecule. Many assumptions that are generally made in turnover studies are not true for short-lived proteins (15, 20) , and biphasic whole body elimination curves have also been seen with Bence Jones proteins (20) . One condition for accurately studying the kinetics of elimination is the rapid exchange between intra-and extravascular compartments. The fact that this condition was probably not fulfilled in this study could explain the biphasic curve and notable extravascular distribution of the half-molecule. Since only protein of the intravascular compartment (or in rapid exchange with it) is catabolized (15) , many more half-molecules were catabolized during the first few days after intravenous injection. Later, a large portion moved to the extravascular compartment and therefore was not catabolized, resulting in a slower overall whole body elimination curve. Evidence for this explanation comes from the relatively constant daily fractional turnover rate which measures only the turnover of the intravascular pool.
The half-molecule with its deletion in the CY3 domain is a unique protein in which to study the localizations of active sites within the Fc fragment. Recently, a number of investigators have studied Fc subfragments having either only the C-y2 domain (21, 22) or only the Ce3 domain (23) for their biological activities. Controversial findings have, however, been reported from different laboratories. Interaction with complement components has been localized to the Cy2 domain by some investigators (22, 24, 25) whereas others recovered activity in peptides of both the Cy2 and Cy3 domain (26) . Similarly, the sites reacting with the Fc cell receptors have been reported to be in the Cy2 domain (27) and in the Ca3 domain (25, 28, 29) . The activities of the half-molecule may help to resolve this controversy. If it is assumed, as shown in the scheme of Fig. 6 , that a given function has several sites on both domains and that at least two sites must be in close proximity in order to express activity, the behavior of the Fc This work was supported by grants from the U. S. Public Health Service (AI 10734-01) and the American Heart Association (73-253).
